Innoviva, Inc. (INVA) — closed signal from December 23, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 23, 2026 — +9.7% at the close.
Predicted vs. what happened
What happened
Reached its target in 65 days.
The thesis — published December 23, 2025
INVA's recent FDA approval for a new oral gonorrhea drug and an analyst raising the price target to $46 put the company back in the spotlight ahead of a planned H2 2026 launch. The stock has fallen a lot recently, which can lead to a fast bounce as traders buy discounted shares. Small-company risks mean keep positions small.
Primary drivers
- FDA approval gives a clear, time-limited reason for buyers to reprice the stock
- Higher analyst price target attracts extra interest from investors
- The stock's recent heavy selling can spark a sharp rebound as buyers step in
- Royalty and asset structure gives the company flexibility around launch timing
How it played out
INVA: target reached in 65 days
Lyra published INVA at $19.98 on 2025-12-23 with a short-term thesis for 25% growth. The thesis pointed to FDA approval for a new oral gonorrhea drug, a higher analyst price target of $46, recent heavy selling, and a royalty and asset structure that gave the company flexibility around launch timing.
Inside the window, the stock reached a peak of $25.15 on 2026-02-26, above the $24.98 target. It got there in 65 days. The peak gain was 25.9%. By 2026-03-23, INVA ended at $21.91. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.